Direction and magnitude of nicotine effects on the fMRI BOLD response are related to nicotine effects on behavioral performance.
Considerable variability across individuals has been reported in both the behavioral and fMRI blood oxygen level-dependent (BOLD) response to nicotine. We aimed to investigate (1) whether there is a heterogeneous effect of nicotine on behavioral and BOLD responses across participants and (2) if heterogeneous BOLD responses are associated with behavioral performance measures. In this double-blind, placebo-controlled, cross-over study, 41 healthy participants (19 smokers)--drawn from a larger population-based sample--performed a visual oddball task after acute challenge with 1 mg nasal nicotine. fMRI data and reaction time were recorded during performance of the task. Across the entire group of subjects, we found increased activation in the anterior cingulate cortex, middle frontal gyrus, superior temporal gyrus, post-central gyrus, planum temporal and frontal pole in the nicotine condition compared with the placebo condition. However, follow-up analyses of this difference in activation between the placebo and nicotine conditions revealed that some participants showed an increase in activation while others showed a decrease in BOLD activation from the placebo to the nicotine condition. A reduction of BOLD activation from placebo to nicotine was associated with a decrease in reaction time and reaction time variability and vice versa, suggesting that it is the direction of BOLD response to nicotine which is related to task performance. We conclude that the BOLD response to nicotine is heterogeneous and that the direction of response to nicotine should be taken into account in future pharmaco-fMRI research on the central action of nicotine.
Department of Psychiatry, Heinrich-Heine University, Düsseldorf, Germany. t.warbrick@fz-juelich.de
Tracy
T
Warbrick
Arian
A
Mobascher
Juergen
J
Brinkmeyer
Francesco
F
Musso
Tony
T
Stoecker
N Jon
NJ
Shah
Simone
S
Vossel
Georg
G
Winterer
D000281:Administration, Intranasal; D000328:Adult; D000704:Analysis of Variance; D001921:Brain / Q000098:blood supply* / Q000187:drug effects*; D001931:Brain Mapping; D002755:Choice Behavior / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D007839:Functional Laterality; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D010100:Oxygen / Q000097:blood; D010775:Photic Stimulation / Q000379:methods; D011930:Reaction Time / Q000187:drug effects; D012907:Smoking / Q000473:pathology*; D055815:Young Adult
D018722:Nicotinic Agonists; D009538:Nicotine; D010100:Oxygen
Electroencephalogr Clin Neurophysiol. 1995 Mar;94(3):191-220
7536154
Curr Opin Pharmacol. 2004 Feb;4(1):36-46
15018837
Magn Reson Med. 1995 May;33(5):636-47
7596267
Nat Neurosci. 2006 Jul;9(7):971-8
16767087
Neuroimage. 2001 Dec;14(6):1370-86
11707093
J Neurosci. 2007 Nov 28;27(48):13082-91
18045902
Hum Brain Mapp. 1994;1(3):210-20
24578041
Neuropsychopharmacology. 2007 May;32(5):1011-20
17063156
Nat Rev Drug Discov. 2009 Sep;8(9):733-50
19721446
Neuroimage. 2008 Apr 1;40(2):869-883
18206391
Hum Mol Genet. 2007 Sep 15;16(18):2165-74
17613539
J Clin Neurophysiol. 1992 Oct;9(4):456-79
1464675
Electroencephalogr Clin Neurophysiol. 1995 Apr;94(4):229-50
7537196
Neuroimage. 2003 Jul;19(3):1002-13
12880828
J Pharmacol Exp Ther. 1982 May;221(2):368-72
7077531
J Cogn Neurosci. 2007 Apr;19(4):658-70
17381256
Int J Psychophysiol. 2010 Aug;77(2):166-75
20538020
Neuroscience. 2002;109(4):757-65
11927157
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12569-74
18723676
J Cogn Neurosci. 2007 Jul;19(7):1081-8
17583985
J Neurosci. 2004 Oct 20;24(42):9353-60
15496671
Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39
16220335
J Nucl Med. 2005 Feb;46(2):240-7
15695782
Br J Addict. 1991 Nov;86(11):1467-76
1777741
Int J Psychophysiol. 2006 May;60(2):172-85
16510201
Neurotoxicol Teratol. 2004 Nov-Dec;26(6):731-5
15451037
Neuroscience. 2006 Feb;137(3):853-64
16309846
J Cereb Blood Flow Metab. 1992 Nov;12(6):900-18
1400644
Hum Brain Mapp. 2002 Nov;17(3):143-55
12391568
Psychopharmacology (Berl). 2009 Sep;205(4):625-33
19488741
Electroencephalogr Clin Neurophysiol. 1998 Feb;106(2):156-64
9741777
Neuropsychopharmacology. 2005 Apr;30(4):810-20
15668726
J Neurosci. 2007 Mar 28;27(13):3477-89
17392464
Cereb Cortex. 2009 Sep;19(9):1990-2000
19073624
Nat Rev Drug Discov. 2008 Jan;7(1):68-83
18064038
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Neuropsychopharmacology. 2008 Mar;33(4):731-8
17551539
Neuroimage. 2009 Apr 1;45(2):549-61
19159693
Hum Brain Mapp. 2007 Apr;28(4):263-74
17133387
Neuroimage. 2005 Nov 1;28(2):362-79
16054841
Neuron. 2002 Oct 24;36(3):539-48
12408855
Brain Res Rev. 2006 Aug;51(2):145-60
16530842
Nat Rev Neurosci. 2001 Jun;2(6):417-24
11389475
Neuroimage. 2002 Oct;17(2):825-41
12377157
Clin Neurophysiol. 2004 Jun;115(6):1374-83
15134705
Biol Psychiatry. 2004 Apr 15;55(8):850-8
15050867
Neuropsychologia. 1971 Mar;9(1):97-113
5146491
Neuroscience. 2008 Mar 18;152(2):381-90
18272290
Neuroimage. 2006 Feb 15;29(4):1311-8
16406256
Clin Pharmacol Ther. 1984 Apr;35(4):499-504
6705448
Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):94-103
10095081
Psychopharmacology (Berl). 2006 Nov;188(4):530-40
16896957
Neuroimage. 2009 Aug 1;47(1):136-47
19345734
J Neurosci. 2008 Jun 4;28(23):5976-82
18524902